What is the clinical evidence from this study?

Study design: Other. Population: Reversal of new oral anticoagulants. Intervention: Prothrombin complex concentrates (PCCs).

What question did this study set out to answer?

To evaluate the existing preclinical and clinical evidence supporting the use of prothrombin complex concentrates (PCCs) for reversing anticoagulation induced by newer oral agents.

October 17, 2013Thrombosis and Haemostasis

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

View Full Paper

Ask AI

Bookmark

Key result

The provided text contains only journal masthead and editorial board information, with no clinical study data available for extraction.

Why the study?

Do prothrombin complex concentrates (PCCs) effectively reverse bleeding induced by new oral anticoagulants?

Population

Patients or animal models with bleeding induced by new oral anticoagulants

Design

Review

Authors

MHMaureane HoffmanDuke University GDGerhard DickneiteBehringwerke (Germany)

Discussion

Member takes

Implication

No clinical data extracted; leaves open PCC efficacy and dosing for NOAC reversal pending prospective trials.

Key Points

To evaluate the existing preclinical and clinical evidence supporting the use of prothrombin complex concentrates (PCCs) for reversing anticoagulation induced by newer oral agents.
Synthesized findings from preclinical animal models and nonbleeding human trials investigating PCC administration for novel oral anticoagulant reversal.
Evaluated comparative evidence for PCCs alongside other potential reversal strategies, including fresh frozen plasma and recombinant activated factor VII.
Preclinical data suggest potential reversal efficacy with PCCs, but human clinical trial evidence in actively bleeding patients remains absent.
Laboratory test normalization following PCC administration fails to correlate consistently with actual clinical cessation of anticoagulant-induced bleeding across various formulations.
PCC therapy is considered a reasonable intervention in life-threatening clinical settings, though lack of clinical trials precludes definitive dosing guidelines or consensus.

Structured PICO

Do prothrombin complex concentrates (PCCs) effectively reverse bleeding induced by new oral anticoagulants?

Population

Patients or animal models with bleeding induced by new oral anticoagulants

Intervention

Prothrombin complex concentrates (PCCs)

Outcome

Reversal of anticoagulant-induced bleeding and coagulopathysafety

Current evidence for using PCCs to reverse new oral anticoagulants is largely preclinical, highlighting a critical need for clinical data before establishing consensus on use or dosing.

Limitations

Lack of clinical data
Reliance on animal models and nonbleeding human subjects
Variation in ability of different PCCs to reverse coagulopathy

Cite This Study

Hoffman et al. (2013) studied Reversal of new oral anticoagulants. Prothrombin complex concentrates (PCCs) was evaluated. The provided text contains only journal masthead and editorial board information, with no clinical study data available for extraction.

synapsesocial.com/papers/6a15f4e7d9ab26d82ed13eba https://doi.org/10.1160/th13-05-0431

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider